SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead asset, ibrexafungerp, is a broad-spectrum, oral/IV antifungal agent representing a novel therapeutic class. On June 1, 2021, ibrexafungerp received its first FDA approval with the trade name BREXAFEMME® (ibrexafungerp tablets).